A phase II trial of ZD1839 (“Iressa”) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract 1166] - Kris,M.G.; Natale,R.B.; Herbst,R.S. (Proc Am Soc Clin Oncol, 2002)